UroGen Pharma to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022

Rhea-AI Summary

UroGen Pharma Ltd. (Nasdaq: URGN) will release its third quarter 2022 financial results on November 10, 2022, before the market opens. Following this, a conference call and live audio webcast will be held at 10:00 AM ET. UroGen focuses on developing treatments for urothelial and specialty cancers, utilizing innovative technologies like their RTGel™ platform. This technology aims to improve local therapy effectiveness. Their products include Jelmyto® for pyelocaliceal solution and investigational UGN-102 for intravesical solution.

Positive

• Innovative treatment technologies, such as RTGel™, could enhance drug effectiveness.
• First commercial product Jelmyto® is already on the market.

Negative

• None.

Conference Call and Webcast Scheduled for Thursday, November 10, 2022 at 10:00 AM ET

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report third quarter 2022 financial results on Thursday, November 10, 2022, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.

A live public webcast of the earnings conference call can be accessed on UroGen’s Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product Jelmyto® (mitomycin) for pyelocaliceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005311/en/

INVESTORS:

Vincent Perrone

vincent.perrone@urogen.com

609-460-3588 ext. 1093

MEDIA:

Cindy Romano

Director, Corporate Communications

cindy.romano@urogen.com

609-460-3583 ext. 1083

Source: UroGen Pharma Ltd.

FAQ

When will UroGen Pharma announce its Q3 2022 financial results?

UroGen Pharma will announce its Q3 2022 financial results on November 10, 2022.

What time is the UroGen Pharma conference call scheduled?

The UroGen Pharma conference call is scheduled for 10:00 AM ET on November 10, 2022.

What products does UroGen Pharma currently have?

UroGen Pharma's current products include Jelmyto® for pyelocaliceal solution and investigational UGN-102 for intravesical solution.

How does UroGen Pharma's RTGel™ technology work?

RTGel™ is a sustained release, hydrogel-based platform designed to improve the therapeutic profiles of existing drugs by enabling longer exposure of the urinary tract tissue to medications.